Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

NCT06792214 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

118

Enrollment

OTHER

Sponsor class

Conditions

SARS CoV-2 Post-Acute Sequelae

Interventions

DRUG: Nirmatrelvir/ritonavir
DRUG: Remdesivir

Sponsor

Mount Sinai Hospital, Canada

Collaborators

[object Object]
[object Object]
[object Object]